Patents by Inventor Melanie Ott

Melanie Ott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Rapid field-deployable detection of SARS-CoV-2 virus
    Patent number: 12577625
    Abstract: The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with SARS-CoV-2 crRNA guide RNAs to detect and quantify the presence of SARS-CoV-2 RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose SARS-CoV-2 infection, quantify the concentration of SARS-CoV-2 RNA present in a sample, identify the presence of different SARS-CoV-2 splice variants, subtypes, or mutations, and to monitor reactivation of SARS-CoV-2 transcription.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: March 17, 2026
    Assignees: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone, The Regents of the University of California
    Inventors: Melanie Ott, Parinaz Fozouni, Jennifer A. Doudna, Daniel A. Fletcher, David Savage, Emeric Charles, Sungmin Son, Gagandeep Renuka Kumar, Neil Switz
  • EPIGENOME EDITORS FOR MODULATING HIV TRANSCRIPTION
    Publication number: 20260028599
    Abstract: BrecOFF is an epigenome editor that specifically targets the HIV promoter, long tandem repeat (LTR), to deposit DNA and histone repressive markers and thereby silencing its transcription and reactivation. BrecOFF comprises of 3 modules (FIG. 1a). The DNMT3A and cofactor DNMT3L are the de novo DNA methylation machinery that marks DNA with repressive methylation marks. The Krüppel associated box (KRAB) domain is a transcriptional repression domain by recruit of TRIM28 repression complex and addition of repressive epigenetic marks on histones.
    Type: Application
    Filed: July 25, 2025
    Publication date: January 29, 2026
    Inventors: Francisco J. Zapatero Belinchon, Melanie Ott, Ulrike C Lange, Martin Volker Hamann
  • HIV OR HCV DETECTION WITH CRISPR-CAS13A
    Publication number: 20250382658
    Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.
    Type: Application
    Filed: January 11, 2025
    Publication date: December 18, 2025
    Inventors: Parinaz Fozouni et al., Melanie Ott, Jennifer A. Doudna
  • Viral Diagnostic using CRISPR RNA combinations and Cas13a enzyme
    Publication number: 20250369058
    Abstract: The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with Influenza A or B crRNA guide RNAs to detect and quantify the presence of Influenza A or B RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose Influenza A or B infection, quantify the concentration of Influenza A or B RNA present in a sample, and identify the presence of different Influenza A subtypes or mutations.
    Type: Application
    Filed: July 7, 2023
    Publication date: December 4, 2025
    Inventors: Gagandeep Renuka Kumar, Melanie Ott, Daniel A. Fletcher
  • HIV or HCV detection with CRISPR-CAS13A
    Patent number: 12215377
    Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: February 4, 2025
    Assignees: The J. David Gladstone Institute, a testamentary trust established under the Will of J. David Gladstone, The Regents of the University of California
    Inventors: Parinaz Fozouni, Melanie Ott, Jennifer A. Doudna
  • HIGH-THROUGHPUT SCREENING OF SARS-COV-2 VARIANTS
    Publication number: 20240318266
    Abstract: Provided herein are compositions and methods to identify mutations in one or more SARS-CoV-2 structural proteins that affect infectivity.
    Type: Application
    Filed: March 25, 2024
    Publication date: September 26, 2024
    Inventors: Taha Yasin Taha, Melanie Ott
  • KINETIC BARCODING TO ENHANCE SPECIFICITY OF CRISPR/CAS REACTIONS
    Publication number: 20240309473
    Abstract: Droplet detection of RNA enables quantification of the absolute amount of target RNA as well as identification of different variant or mutant RNA species. As described herein. RNA detection with high sensitivity and multiplexed specificity can be achieved with short detection times by encapsulating the Cas reaction in droplets and monitoring enzyme kinetics fluorescently.
    Type: Application
    Filed: July 1, 2022
    Publication date: September 19, 2024
    Inventors: Daniel Fletcher, Sungmin Son, Melanie Ott
  • ASSAY FOR SARS-CoV-2 INFECTION OF VULNERABLE HUMAN CELLS
    Publication number: 20240295544
    Abstract: Provided herein are methods and compositions useful for identifying compounds that can inhibit SARS-CoV-2 infection or the effects thereof, especially in cardiomyocytes (CMs), which are highly infectible by SARS-CoV-2 corona viruses.
    Type: Application
    Filed: August 24, 2021
    Publication date: September 5, 2024
    Inventors: Todd C. McDevitt, Bruce Conklin, Melanie Ott, Juan Perez-Bermejo, Michael Sungwon Kang, Sarah Rockwood, Camille Simoneau, Gokul Ramadoss, David Joy
  • RAPID GENERATION OF INFECTIOUS CLONES
    Publication number: 20240209381
    Abstract: Provided herein is a novel cloning system with rational fragment design and single-pot ligation (pGLUE) that allows systematic exchange and mutagenesis of genes and rapid construction of entire molecular clones and replicons of virus within days.
    Type: Application
    Filed: December 21, 2023
    Publication date: June 27, 2024
    Inventors: Taha Yasin Taha, Melanie Ott, Takako Tabata
  • Compositions and methods for reactivating latent immunodeficiency virus
    Patent number: 11807852
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: November 7, 2023
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Daniela Boehm
  • COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS AND/OR TREATING IMMUNODEFICIENCY VIRUS INFECTION
    Publication number: 20220193209
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: January 16, 2020
    Publication date: June 23, 2022
    Inventors: Albert Vallejo Gracia, Emilie Besnard, Melanie Ott, Eric Verdin
  • COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS
    Publication number: 20220090085
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: July 20, 2021
    Publication date: March 24, 2022
    Inventors: Melanie Ott, Daniela Boehm
  • RAPID FIELD-DEPLOYABLE DETECTION OF SARS-CoV-2 VIRUS
    Publication number: 20210348243
    Abstract: The present disclosure relates to methods using CRISPR-Cas13 enzyme, complexed with SARS-CoV-2 crRNA guide RNAs to detect and quantify the presence of SARS-CoV-2 RNA in a sample with enhanced specificity and sensitivity. These methods can be used to diagnose SARS-CoV-2 infection, quantify the concentration of SARS-CoV-2 RNA present in a sample, identify the presence of different SARS-CoV-2 splice variants, subtypes, or mutations, and to monitor reactivation of SARS-CoV-2 transcription.
    Type: Application
    Filed: March 18, 2021
    Publication date: November 11, 2021
    Inventors: Melanie Ott, Parinaz Fozouni, Jennifer A. Doudna, Daniel A. Fletcher, David Savage, Emeric Charles, Sungmin Son, Gagandeep Renuka Kumar, Neil Switz
  • HIV OR HCV DETECTION WITH CRISPR-CAS13A
    Publication number: 20210348212
    Abstract: The present disclosure relates to methods using CRISPR-Cas13a enzyme, complexed with HIV or HCV crRNAs to specifically and sensitively detect and quantify the presence of HIV or HCV RNA in a sample. These methods can be used to diagnose HIV or HCV infection, quantify the concentration of HIV or HCV RNA present in a sample, identify the presence of different HIV or HCV splice variants, subtypes, or mutations, and to monitor reactivation of HIV or HCV transcription.
    Type: Application
    Filed: September 6, 2019
    Publication date: November 11, 2021
    Inventors: Parinaz Fozouni, Melanie Ott, Jennifer A. Doudna
  • Compositions and methods for reactivating latent immunodeficiency virus
    Patent number: 11098309
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: August 24, 2021
    Assignee: The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Gladstone
    Inventors: Melanie Ott, Daniela Boehm
  • COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS
    Publication number: 20190338289
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 7, 2019
    Inventors: Melanie Ott, Daniela Boehm
  • Compositions and methods for reactivating latent immunodeficiency virus
    Patent number: 10351853
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: July 16, 2019
    Assignee: The J. David Gladstone Institutes
    Inventors: Melanie Ott, Daniela Boehm
  • Compositions and methods for treating Dengue virus infection
    Patent number: 10004751
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 26, 2018
    Assignees: The J. David Gladstone Institutes, The Regents of the University of California
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine
  • COMPOSITIONS AND METHODS FOR REACTIVATING LATENT IMMUNODEFICIENCY VIRUS
    Publication number: 20180002699
    Abstract: The present disclosure provides compositions and methods for reactivating latent immunodeficiency virus and/or reducing transcription of HIV integrated into the genome of an HIV-infected cell. The present disclosure provides compositions and methods for treating an immunodeficiency virus infection.
    Type: Application
    Filed: April 14, 2017
    Publication date: January 4, 2018
    Inventors: Melanie Ott, Daniela Boehm
  • COMPOSITIONS AND METHODS FOR TREATING DENGUE VIRUS INFECTION
    Publication number: 20170209460
    Abstract: The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.
    Type: Application
    Filed: July 7, 2015
    Publication date: July 27, 2017
    Inventors: Melanie Ott, Andrew S. Kondratowicz, Nevan John Krogan, Priya Shirish Shah, Krystal Ann Fontaine